Bukumirić, Zoran

Link to this page

Authority KeyName Variants
orcid::0000-0002-7609-4504
  • Bukumirić, Zoran (3)
Projects

Author's Bibliography

Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study

Kopčalić, Katarina; Petrović, Nina; Stanojković, Tatjana P.; Stanković, Vesna; Bukumirić, Zoran; Roganović, Jelena; Mališić, Emina; Nikitović, Marina

(Elsevier GmbH, 2019)

TY  - JOUR
AU  - Kopčalić, Katarina
AU  - Petrović, Nina
AU  - Stanojković, Tatjana P.
AU  - Stanković, Vesna
AU  - Bukumirić, Zoran
AU  - Roganović, Jelena
AU  - Mališić, Emina
AU  - Nikitović, Marina
PY  - 2019
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2594
AB  - Introduction: Nearly sixty percent of patients with prostate cancer (PCa) undergo radiation therapy (RT). During the course of treatment patients may experience normal tissue reactions. It is a well established fact that genetic and epigenetic mechanisms, such as microRNA (miRNA) level changes might be associated with radiotoxicity, as a response to irradiation. 
Materials and methods: This is the first study that has investigated levels of radiosensory miRNAs in association with acute genitourinary radiotoxicity extracted from peripheral blood mononuclear cells (PBCs), in three points; before RT (BRT), after RT (ART) and on the first control examination (FCONT). We measured levels of miR-21/146a/155 expression by quantitative real-time PCR (qRT-PCR), comparative ΔΔCt method, in fifteen patients with localized prostate cancer, treated with three-dimensional conformal radiotherapy (3DCRT). Nine subjects have experienced acute genitourinary (GU) radiotoxicity whereas six where without GU radiotoxicity. 
Results: Firstly, we detected the highest levels of miR-21 in ART group (p = 0.043) in the patients with acute GU radiotoxicity. Secondly, we found trend towards higher miR-21 levels and significantly higher levels of miR-146a/155 within the patients with acute GU toxicity than in patients without (p = 0.068, p = 0.016, and p = 0.010, respectively). Thirdly, we detected significant change in miR-146a/155 levels within the patients without acute GU radiotoxicity during RT p = 0.042, and p = 0.041, respectively). 
Conclusion: miR-21/146a/155 might be useful potential factors of radiosensitivity and acute genitourinary radiotoxicity in prostate cancer patients. miRNA might have great potential as predictors of various pathological conditions extracted from PBMCs.
PB  - Elsevier GmbH
T2  - Pathology - Research and Practice
T1  - Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study
VL  - 215
IS  - 4
SP  - 626
EP  - 631
DO  - 10.1016/j.prp.2018.12.007
ER  - 
@article{
author = "Kopčalić, Katarina and Petrović, Nina and Stanojković, Tatjana P. and Stanković, Vesna and Bukumirić, Zoran and Roganović, Jelena and Mališić, Emina and Nikitović, Marina",
year = "2019",
abstract = "Introduction: Nearly sixty percent of patients with prostate cancer (PCa) undergo radiation therapy (RT). During the course of treatment patients may experience normal tissue reactions. It is a well established fact that genetic and epigenetic mechanisms, such as microRNA (miRNA) level changes might be associated with radiotoxicity, as a response to irradiation. 
Materials and methods: This is the first study that has investigated levels of radiosensory miRNAs in association with acute genitourinary radiotoxicity extracted from peripheral blood mononuclear cells (PBCs), in three points; before RT (BRT), after RT (ART) and on the first control examination (FCONT). We measured levels of miR-21/146a/155 expression by quantitative real-time PCR (qRT-PCR), comparative ΔΔCt method, in fifteen patients with localized prostate cancer, treated with three-dimensional conformal radiotherapy (3DCRT). Nine subjects have experienced acute genitourinary (GU) radiotoxicity whereas six where without GU radiotoxicity. 
Results: Firstly, we detected the highest levels of miR-21 in ART group (p = 0.043) in the patients with acute GU radiotoxicity. Secondly, we found trend towards higher miR-21 levels and significantly higher levels of miR-146a/155 within the patients with acute GU toxicity than in patients without (p = 0.068, p = 0.016, and p = 0.010, respectively). Thirdly, we detected significant change in miR-146a/155 levels within the patients without acute GU radiotoxicity during RT p = 0.042, and p = 0.041, respectively). 
Conclusion: miR-21/146a/155 might be useful potential factors of radiosensitivity and acute genitourinary radiotoxicity in prostate cancer patients. miRNA might have great potential as predictors of various pathological conditions extracted from PBMCs.",
publisher = "Elsevier GmbH",
journal = "Pathology - Research and Practice",
title = "Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study",
volume = "215",
number = "4",
pages = "626-631",
doi = "10.1016/j.prp.2018.12.007"
}
Kopčalić, K., Petrović, N., Stanojković, T. P., Stanković, V., Bukumirić, Z., Roganović, J., Mališić, E.,& Nikitović, M.. (2019). Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study. in Pathology - Research and Practice
Elsevier GmbH., 215(4), 626-631.
https://doi.org/10.1016/j.prp.2018.12.007
Kopčalić K, Petrović N, Stanojković TP, Stanković V, Bukumirić Z, Roganović J, Mališić E, Nikitović M. Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study. in Pathology - Research and Practice. 2019;215(4):626-631.
doi:10.1016/j.prp.2018.12.007 .
Kopčalić, Katarina, Petrović, Nina, Stanojković, Tatjana P., Stanković, Vesna, Bukumirić, Zoran, Roganović, Jelena, Mališić, Emina, Nikitović, Marina, "Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study" in Pathology - Research and Practice, 215, no. 4 (2019):626-631,
https://doi.org/10.1016/j.prp.2018.12.007 . .
19
8
15

Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study

Kopcalić, Katarina; Petrović, Nina; Stanojković, Tatjana P.; Stanković, Vesna; Bukumirić, Zoran; Roganović, Jelena; Malisić, Emina; Nikitović, Marina

(Elsevier Gmbh, Munich, 2019)

TY  - JOUR
AU  - Kopcalić, Katarina
AU  - Petrović, Nina
AU  - Stanojković, Tatjana P.
AU  - Stanković, Vesna
AU  - Bukumirić, Zoran
AU  - Roganović, Jelena
AU  - Malisić, Emina
AU  - Nikitović, Marina
PY  - 2019
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2391
AB  - Introduction: Nearly sixty percent of patients with prostate cancer (PCa) undergo radiation therapy (RT). During the course of treatment patients may experience normal tissue reactions. It is a well established fact that genetic and epigenetic mechanisms, such as microRNA (miRNA) level changes might be associated with radiotoxicity, as a response to irradiation. Materials and methods: This is the first study that has investigated levels of radiosensory miRNAs in association with acute genitourinary radiotoxicity extracted from peripheral blood mononuclear cells (PBCs), in three points; before RT (BRT), after RT (ART) and on the first control examination (FCONT). We measured levels of miR-21/146a/155 expression by quantitative real-time PCR (qRT-PCR), comparative Delta Delta Ct method, in fifteen patients with localized prostate cancer, treated with three-dimensional conformal radiotherapy (3DCRT). Nine subjects have experienced acute genitourinary (GU) radiotoxicity whereas six where without GU radiotoxicity. Results: Firstly, we detected the highest levels of miR-21 in ART group (p = 0.043) in the patients with acute GU radiotoxicity. Secondly, we found trend towards higher miR-21 levels and significantly higher levels of miR-146a/155 within the patients with acute GU toxicity than in patients without (p = 0.068, p = 0.016, and p = 0.010, respectively). Thirdly, we detected significant change in miR-146a/155 levels within the patients without acute GU radiotoxicity during RT p = 0.042, and p = 0.041, respectively). Conclusion: miR-21/146a/155 might be useful potential factors of radiosensitivity and acute genitourinary radiotoxicity in prostate cancer patients. miRNA might have great potential as predictors of various pathological conditions extracted from PBMCs.
PB  - Elsevier Gmbh, Munich
T2  - Pathology Research & Practice
T1  - Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study
VL  - 215
IS  - 4
SP  - 626
EP  - 631
DO  - 10.1016/j.prp.2018.12.007
ER  - 
@article{
author = "Kopcalić, Katarina and Petrović, Nina and Stanojković, Tatjana P. and Stanković, Vesna and Bukumirić, Zoran and Roganović, Jelena and Malisić, Emina and Nikitović, Marina",
year = "2019",
abstract = "Introduction: Nearly sixty percent of patients with prostate cancer (PCa) undergo radiation therapy (RT). During the course of treatment patients may experience normal tissue reactions. It is a well established fact that genetic and epigenetic mechanisms, such as microRNA (miRNA) level changes might be associated with radiotoxicity, as a response to irradiation. Materials and methods: This is the first study that has investigated levels of radiosensory miRNAs in association with acute genitourinary radiotoxicity extracted from peripheral blood mononuclear cells (PBCs), in three points; before RT (BRT), after RT (ART) and on the first control examination (FCONT). We measured levels of miR-21/146a/155 expression by quantitative real-time PCR (qRT-PCR), comparative Delta Delta Ct method, in fifteen patients with localized prostate cancer, treated with three-dimensional conformal radiotherapy (3DCRT). Nine subjects have experienced acute genitourinary (GU) radiotoxicity whereas six where without GU radiotoxicity. Results: Firstly, we detected the highest levels of miR-21 in ART group (p = 0.043) in the patients with acute GU radiotoxicity. Secondly, we found trend towards higher miR-21 levels and significantly higher levels of miR-146a/155 within the patients with acute GU toxicity than in patients without (p = 0.068, p = 0.016, and p = 0.010, respectively). Thirdly, we detected significant change in miR-146a/155 levels within the patients without acute GU radiotoxicity during RT p = 0.042, and p = 0.041, respectively). Conclusion: miR-21/146a/155 might be useful potential factors of radiosensitivity and acute genitourinary radiotoxicity in prostate cancer patients. miRNA might have great potential as predictors of various pathological conditions extracted from PBMCs.",
publisher = "Elsevier Gmbh, Munich",
journal = "Pathology Research & Practice",
title = "Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study",
volume = "215",
number = "4",
pages = "626-631",
doi = "10.1016/j.prp.2018.12.007"
}
Kopcalić, K., Petrović, N., Stanojković, T. P., Stanković, V., Bukumirić, Z., Roganović, J., Malisić, E.,& Nikitović, M.. (2019). Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study. in Pathology Research & Practice
Elsevier Gmbh, Munich., 215(4), 626-631.
https://doi.org/10.1016/j.prp.2018.12.007
Kopcalić K, Petrović N, Stanojković TP, Stanković V, Bukumirić Z, Roganović J, Malisić E, Nikitović M. Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study. in Pathology Research & Practice. 2019;215(4):626-631.
doi:10.1016/j.prp.2018.12.007 .
Kopcalić, Katarina, Petrović, Nina, Stanojković, Tatjana P., Stanković, Vesna, Bukumirić, Zoran, Roganović, Jelena, Malisić, Emina, Nikitović, Marina, "Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study" in Pathology Research & Practice, 215, no. 4 (2019):626-631,
https://doi.org/10.1016/j.prp.2018.12.007 . .
19
8
15

The use of hyaluronic and aminocaproic acid in the treatment of alveolar osteitis

Dubovina, Dejan; Mihailović, Branko; Bukumirić, Zoran; Vlahović, Zoran; Miladinović, Milan; Miković, Nikola; Lazić, Zoran

(Vojnomedicinska akademija - Institut za naučne informacije, Beograd, 2016)

TY  - JOUR
AU  - Dubovina, Dejan
AU  - Mihailović, Branko
AU  - Bukumirić, Zoran
AU  - Vlahović, Zoran
AU  - Miladinović, Milan
AU  - Miković, Nikola
AU  - Lazić, Zoran
PY  - 2016
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2076
AB  - Background/Aim. Alveolar osteitis (AO), also known as "dry socket", is relatively common post-extraction complication. It probably occurs due to excessive fibrinolytic activity in the coagulum and is characterized by intense pain sensations. The aim of this clinical study was to examine the role of hyaluronic acid and aminocaproic acid in the treatment of AO. Methods. The study included 60 patients with the clinical diagnosis of AO. All the patients were divided into two groups of 30 patients each according to the applied non-pharmacological measure: irrigation - irrigation of dry socket with sterile saline; curettage - careful curettage. Both of these groups were further divided into three subgroups regarding the applied treatment (hyaluronic acid; hyaluronic acid + aminocaproic acid; Alvogyl®, an anesthetic and antiseptic paste), each with 10 patients, according to the following protocol: 0.2 mL of hyaluronic acid in the form of a 0.8% gel; 2 mL of aminocaproic acid and hyaluronic acid; Alvogyl®. During each visit, scheduled for every two days until complete absence of painful sensations, the patients had the therapeutic method repeated as at the first examination. At each control visit the number of present symptoms and signs of AO was recorded, as well as the level of pain (measured with a visual analogue scale). Results. With the use of hyaluronic acid, with or without aminocaproic one, a statistically significantly faster reduction in pain sensations was achieved, along with the reduction in the number of symptoms and signs of AO compared to the use of Alvogyl®. Conclusion. Hyaluronic acid, applied alone or in combination with aminocaproic acid significantly reduces pain sensation, thus it can be successfully used in the treatment of AO.
AB  - Uvod/Cilj. Alveolitis je relativno česta postekstrakciona komplikacija. Nastaje, najverovatnije, usled izrazite fibrinolitičke aktivnosti u koagulumu, a karakteriše se pojavom intezivnog bola. Cilj ove kliničke studije bio je da se ispita mogućnost primene hijaluronske i aminokapronske kiseline u terapiji alveolitisa. Metode. Studija je uključila 60 pacijenata sa kliničkom dijagnozom alveolitisa. U odnosu na primenjenu nefarmakološku meru svi pacijenti su bili podeljeni u dve grupe sa po 30 pacijenata: ispiranje - ispiranje obolele alveole sterilnim fiziološkim rastvorom; kiretaža - pažljiva kiretaža. Obe ove grupe, u odnosu na primenjeni tretman [(hijaluronska kiselina, hijaluronska kiselina + aminokapronska kiselina, Alvogyl® (kombinacija anestetika i antiseptika u obliku paste)], bile su podeljene u tri podgrupe sa po 10 pacijenata po sledećem protokolu: 0,2 mL hijaluronske kiseline u obliku 0.8% gela; 2 mL aminokapronske kiseline i hijaluronske kiseline; Alvogyl®. Na kontrolnim pregledima, zakazanim na svaka dva dana do potpunog prestanka bolnih senzacija, pacijentima je ponavljana terapijska opcija sa prvog pregleda. Evidentiran je broj prisutnih simptoma i znakova alveolitisa kod pacijenata, kao i nivo bola (meren pomoću vizuelno-analogne skale). Rezultati. Primenom hijaluronske kiseline, sa ili bez aminokapronske kiseline, postignuto je statistički značajno brže sniženje bolnih senzacija kao i smanjenje broja prisutnih simptoma i znakova alveolitisa u odnosu na upotrebu Alvogyl®-a. Zaključak. Hijaluroska kiselina, samostalno ili u kombinaciji sa aminokapronskom kiselinom, značajno snižava bol, te se može uspešno primenjivati u terapiji alveolitisa.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - The use of hyaluronic and aminocaproic acid in the treatment of alveolar osteitis
T1  - Primena hijaluronske i aminokapronske kiseline u terapiji alveolitisa
VL  - 73
IS  - 11
SP  - 1010
EP  - 1015
DO  - 10.2298/VSP150304125D
ER  - 
@article{
author = "Dubovina, Dejan and Mihailović, Branko and Bukumirić, Zoran and Vlahović, Zoran and Miladinović, Milan and Miković, Nikola and Lazić, Zoran",
year = "2016",
abstract = "Background/Aim. Alveolar osteitis (AO), also known as "dry socket", is relatively common post-extraction complication. It probably occurs due to excessive fibrinolytic activity in the coagulum and is characterized by intense pain sensations. The aim of this clinical study was to examine the role of hyaluronic acid and aminocaproic acid in the treatment of AO. Methods. The study included 60 patients with the clinical diagnosis of AO. All the patients were divided into two groups of 30 patients each according to the applied non-pharmacological measure: irrigation - irrigation of dry socket with sterile saline; curettage - careful curettage. Both of these groups were further divided into three subgroups regarding the applied treatment (hyaluronic acid; hyaluronic acid + aminocaproic acid; Alvogyl®, an anesthetic and antiseptic paste), each with 10 patients, according to the following protocol: 0.2 mL of hyaluronic acid in the form of a 0.8% gel; 2 mL of aminocaproic acid and hyaluronic acid; Alvogyl®. During each visit, scheduled for every two days until complete absence of painful sensations, the patients had the therapeutic method repeated as at the first examination. At each control visit the number of present symptoms and signs of AO was recorded, as well as the level of pain (measured with a visual analogue scale). Results. With the use of hyaluronic acid, with or without aminocaproic one, a statistically significantly faster reduction in pain sensations was achieved, along with the reduction in the number of symptoms and signs of AO compared to the use of Alvogyl®. Conclusion. Hyaluronic acid, applied alone or in combination with aminocaproic acid significantly reduces pain sensation, thus it can be successfully used in the treatment of AO., Uvod/Cilj. Alveolitis je relativno česta postekstrakciona komplikacija. Nastaje, najverovatnije, usled izrazite fibrinolitičke aktivnosti u koagulumu, a karakteriše se pojavom intezivnog bola. Cilj ove kliničke studije bio je da se ispita mogućnost primene hijaluronske i aminokapronske kiseline u terapiji alveolitisa. Metode. Studija je uključila 60 pacijenata sa kliničkom dijagnozom alveolitisa. U odnosu na primenjenu nefarmakološku meru svi pacijenti su bili podeljeni u dve grupe sa po 30 pacijenata: ispiranje - ispiranje obolele alveole sterilnim fiziološkim rastvorom; kiretaža - pažljiva kiretaža. Obe ove grupe, u odnosu na primenjeni tretman [(hijaluronska kiselina, hijaluronska kiselina + aminokapronska kiselina, Alvogyl® (kombinacija anestetika i antiseptika u obliku paste)], bile su podeljene u tri podgrupe sa po 10 pacijenata po sledećem protokolu: 0,2 mL hijaluronske kiseline u obliku 0.8% gela; 2 mL aminokapronske kiseline i hijaluronske kiseline; Alvogyl®. Na kontrolnim pregledima, zakazanim na svaka dva dana do potpunog prestanka bolnih senzacija, pacijentima je ponavljana terapijska opcija sa prvog pregleda. Evidentiran je broj prisutnih simptoma i znakova alveolitisa kod pacijenata, kao i nivo bola (meren pomoću vizuelno-analogne skale). Rezultati. Primenom hijaluronske kiseline, sa ili bez aminokapronske kiseline, postignuto je statistički značajno brže sniženje bolnih senzacija kao i smanjenje broja prisutnih simptoma i znakova alveolitisa u odnosu na upotrebu Alvogyl®-a. Zaključak. Hijaluroska kiselina, samostalno ili u kombinaciji sa aminokapronskom kiselinom, značajno snižava bol, te se može uspešno primenjivati u terapiji alveolitisa.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "The use of hyaluronic and aminocaproic acid in the treatment of alveolar osteitis, Primena hijaluronske i aminokapronske kiseline u terapiji alveolitisa",
volume = "73",
number = "11",
pages = "1010-1015",
doi = "10.2298/VSP150304125D"
}
Dubovina, D., Mihailović, B., Bukumirić, Z., Vlahović, Z., Miladinović, M., Miković, N.,& Lazić, Z.. (2016). The use of hyaluronic and aminocaproic acid in the treatment of alveolar osteitis. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 73(11), 1010-1015.
https://doi.org/10.2298/VSP150304125D
Dubovina D, Mihailović B, Bukumirić Z, Vlahović Z, Miladinović M, Miković N, Lazić Z. The use of hyaluronic and aminocaproic acid in the treatment of alveolar osteitis. in Vojnosanitetski pregled. 2016;73(11):1010-1015.
doi:10.2298/VSP150304125D .
Dubovina, Dejan, Mihailović, Branko, Bukumirić, Zoran, Vlahović, Zoran, Miladinović, Milan, Miković, Nikola, Lazić, Zoran, "The use of hyaluronic and aminocaproic acid in the treatment of alveolar osteitis" in Vojnosanitetski pregled, 73, no. 11 (2016):1010-1015,
https://doi.org/10.2298/VSP150304125D . .
14
3
9